Brian Lian

LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial

Kenneth E. Homer, R. Loomba, J. Neutel, 2019, Journal of Hepatology.

A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia

D. Koeberl, S. Refetoff, P. Yen, 2019 .

Abstract 14497: Reduction of Atherogenic Lipoprotein (a) and Apolipoprotein B in Humans With the Selective Thyroid Receptor Beta Agonist Vk2809

S. Schoenfeld, R. Hanley, Brian Lian, 2016 .

A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia (GSD Ia).

D. Koeberl, S. Refetoff, P. Yen, 2019, Thyroid : official journal of the American Thyroid Association.